OTCMKTS:DCTHD

Delcath Systems (DCTHD) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$5.42
$5.80
50-Day Range
N/A
52-Week Range
$1.22
$63,000.00
Volume
250,155 shs
Average Volume
771 shs
Market Capitalization
$220,600.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DCTHD stock logo

About Delcath Systems Stock (OTCMKTS:DCTHD)

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

DCTHD Stock News Headlines

Delcath Systems Stock (NASDAQ:DCTH) Insider Trades
How Biden has already won 2024
Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.
Delcath Liver Tumor Data Improve
How Biden has already won 2024
Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.
Delcath Readies Pivotal Trial Results
Best iPad POS Systems Of 2023
What is the digestive system?
Delcath: Safety Questions Behind FDA Delay
Delcath Systems Announces up to $85 Million Financing
Delcath Systems Inc. Q4 Loss increases, misses estimates
Delcath Announces FDA's Acceptance Of NDA Resubmission Of Hepzato Kit
Delcath Systems Announces Resubmission Of NDA For Hepzato Kit
Delcath Systems slips despite Q3 beat
DCTH Delcath Systems, Inc.
Delcath Systems Inc. Q2 Loss increases, misses estimates
Delcath Systems to Host Second Quarter 2022 Results
See More Headlines
Receive DCTHD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2016
Today
5/08/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:DCTHD
Previous Symbol
NASDAQ:DCTH
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-19,220,000.00
Net Margins
-1,546.38%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.41 million
Book Value
($1,036.00) per share

Miscellaneous

Free Float
N/A
Market Cap
$220,600.00
Optionable
Not Optionable
Beta
-0.03
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Roger G. Stoll Ph.D. (Age 74)
    Chairman of the Board
  • Jennifer K. Simpson Ph.D. (Age 48)
    President, Chief Executive Officer, Director
  • Barbra C. Keck (Age 39)
    Chief Financial Officer, Secretary
  • John Purpura (Age 55)
    Executive Vice President - Global Head of Operations
  • Simon C. Pedder Ph.D. (Age 56)
    Director
  • William Dodge Rueckert (Age 64)
    Independent Director
  • Marco Taglietti M.D. (Age 57)
    Independent Director

DCTHD Stock Analysis - Frequently Asked Questions

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (OTCMKTS:DCTHD) posted its quarterly earnings data on Friday, November, 11th. The medical device company reported ($231.00) EPS for the quarter, topping analysts' consensus estimates of ($1,151.50) by $920.50. The medical device company earned $0.44 million during the quarter. During the same quarter in the previous year, the company earned ($686.00) earnings per share.

When did Delcath Systems' stock split?

Delcath Systems's stock reverse split before market open on Monday, November 6th 2017. The 1-350 reverse split was announced on Friday, November 3rd 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 3rd 2017. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

This page (OTCMKTS:DCTHD) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners